2009

In this article, Kim Slocum, former Director, Strategic Planning & Business Development at AstraZeneca describes several alternative future health care system scenarios and makes a case for the industry to support Comparative Effectiveness Research or CER.

In the future, will the FDA also be pulled into social media by a major Rx drug recall? What can the drug industry learn from the FDA's use of social media and will FDA's example help guide the industry toward best practices in this area? This article describes FDA's social networking initiatives in context of these questions.

This article reviews the medical privacy restrictions included in the American Recovery and Reinvestment Act, which President Obama signed into law on Feb. 17, 2009, and discusses the impact these restrictions might have on pharmaceutical marketing.

Welcome to the March 2009 issue of Pharma Marketing News.

Welcome to the March 2009 issue of Pharma Marketing News.

This article presents a summary of a recent TNS Healthcare webinar and personal conversations with presenters conducted beforehand. Included are NEW research results about how US and European physicians rate pharmaceutical companies against a number of customer value points that are important in achieving success with the new sales model.

The pharmaceutical industry must find ways to utilize the new media tools that other industries use while ensuring compliance with FDA regulations. The good news is we can! The author summaries the content of the book and offers practical guidelines for the pharma marketers.

This article summarizes a recent discussion between eyeforpharma's Editor Lisa Roner and Hans Nagl, Promotion Response Modelling Manager, Shire, about how the current economy and changing pharma landscape is impacting program effectiveness measures.

Welcome to the February 2009 issue of Pharma Marketing News.

Welcome to the February 2009 issue of Pharma Marketing News.